Area of research
Neurology · Cancer Research
Research interest
Research interests include Neuroblastoma Research and Treatments, Cancer, Hypoxia, and Metabolism, Protein Degradation and Inhibitors, and Childhood Cancer Survivors' Quality of Life.
Current treatment strategies for first relapse of high-risk neuroblastoma
Organoid drug profiling identifies methotrexate as a therapy for SCCOHT, a rare pediatric cancer
Exploring high-throughput drug sensitivity testing in neuroblastoma cell lines and patient-derived tumor organoids in the era of precision medicine
Accelerating Drug Development for Neuroblastoma: Consensus Statement From the Third Neuroblastoma Drug Development Strategy Forum
Small round cell sarcoma tumoroid biobank reveals CIC::DUX4 sarcoma vulnerability to MCL-1 inhibition
Integrative analysis of neuroblastoma by single-cell RNA sequencing identifies the NECTIN2-TIGIT axis as a target for immunotherapy
Effective methods for bulk RNA-seq deconvolution using scnRNA-seq transcriptomes
Outcome of Children and Adolescents With Relapsed/Refractory/Progressive Malignancies Treated With Molecularly Informed Targeted Drugs in the Pediatric Precision Oncology Registry INFORM
Systematic discovery of gene fusions in pediatric cancer by integrating RNA-seq and WGS
Combination Early-Phase Trials of Anticancer Agents in Children and Adolescents
The potential of PARP as a therapeutic target across pediatric solid malignancies
Adoptive cell therapy in paediatric extracranial solid tumours: current approaches and future challenges
MEK inhibition causes BIM stabilization and increased sensitivity to BCL-2 family member inhibitors in RAS-MAPK-mutated neuroblastoma
Abstract 234: ITCC-P4: Genomic profiling and analyses of pediatric patient tumor and patient-derived xenograft (PDX) models for high throughput <i>in vivo</i> testing
Mutations in ALK signaling pathways conferring resistance to ALK inhibitor treatment lead to collateral vulnerabilities in neuroblastoma cells
Implementation of paediatric precision oncology into clinical practice: The Individualized Therapies for Children with cancer program ‘iTHER’
Mesenchymal tumor organoid models recapitulate rhabdomyosarcoma subtypes
RRM2 enhances MYCN-driven neuroblastoma formation and acts as a synergistic target with CHK1 inhibition
Mutational spectrum of <i>ATRX</i> aberrations in neuroblastoma and associated patient and tumor characteristics
Target actionability review to evaluate CDK4/6 as a therapeutic target in paediatric solid and brain tumours
INSP-15. ITCC-P4: A sustainable platform of molecularly well-characterized PDX models of pediatric cancers for high throughput<i>in vivo</i> testing
Effective methods for bulk RNA-Seq deconvolution using scnRNA-Seq transcriptomes
The Pediatric Precision Oncology INFORM Registry: Clinical Outcome and Benefit for Patients with Very High-Evidence Targets
Organoid-based drug screening reveals neddylation as therapeutic target for malignant rhabdoid tumors
The Landscape of Pediatric Precision Oncology: Program Design, Actionable Alterations, and Clinical Trial Development
International Consensus on Minimum Preclinical Testing Requirements for the Development of Innovative Therapies For Children and Adolescents with Cancer
Target Actionability Review: a systematic evaluation of replication stress as a therapeutic target for paediatric solid malignancies
Simple, fast and efficient iTOP-mediated delivery of CRISPR/Cas9 RNP in difficult-to-transduce human cells including primary T cells
High-Throughput Screening Identifies Idasanutlin as a Resensitizing Drug for Venetoclax-Resistant Neuroblastoma Cells
An organoid biobank for childhood kidney cancers that captures disease and tissue heterogeneity